NFE2L2 and colonic neoplasm: We found that the compound-mediated cytotoxic effect against colon cancer cells was greatly improved by the concomitant inhibition of NRF2 and BiP, highlighting a critical interplay between these two molecules and their pathways that cancer cells exploit to resist to the cytotoxic effect of the anticancer therapies.